At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 86 enrolled
Drug / intervention
DS-8201adrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Open-label Study of DS-8201a in Subjects With HER2-expressing Advanced Colorectal Cancer
In Brief
A Phase 2 clinical trial evaluating DS-8201a for Colorectal Neoplasm. Completed, enrolled 86 participants across 25 sites in 5 countries.
Detailed Summary
The main objective of this study is to test the safety and effectiveness of DS-8201a for participants with HER2-expressing advanced colorectal cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Neoplasm
CountriesItaly, Japan, Spain, United Kingdom, United States
CollaboratorsDaiichi Sankyo, AstraZeneca
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedDec 2017
Enrollment StartFeb 2018
Primary CompletionAug 2019
Study CompletionNov 2020
TodayJul 2026
First PostedDec 28, 2017
Enrollment StartFeb 23, 2018
Primary CompletionAug 9, 2019
Study CompletionNov 10, 2020
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 8.5 years ago
Interventions
DS-8201adrug
DS-8201a is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration